Maxwell Skor
Stock Analyst at Morgan Stanley
(2.86)
# 1,581
Out of 5,127 analysts
6
Total ratings
66.67%
Success rate
43.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Equal-Weight | $126 → $144 | $170.27 | -15.43% | 1 | Aug 21, 2025 | |
| ASND Ascendis Pharma | Assumes: Overweight | $250 | $208.75 | +19.76% | 1 | Jul 3, 2025 | |
| SANA Sana Biotechnology | Assumes: Overweight | $12 | $4.52 | +165.49% | 1 | Jul 3, 2025 | |
| TCRX TScan Therapeutics | Assumes: Overweight | $10 | $1.18 | +747.46% | 1 | Mar 14, 2025 | |
| IVVD Invivyd | Maintains: Overweight | $9.5 → $3.55 | $2.51 | +41.43% | 2 | Nov 20, 2024 |
Insmed
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $126 → $144
Current: $170.27
Upside: -15.43%
Ascendis Pharma
Jul 3, 2025
Assumes: Overweight
Price Target: $250
Current: $208.75
Upside: +19.76%
Sana Biotechnology
Jul 3, 2025
Assumes: Overweight
Price Target: $12
Current: $4.52
Upside: +165.49%
TScan Therapeutics
Mar 14, 2025
Assumes: Overweight
Price Target: $10
Current: $1.18
Upside: +747.46%
Invivyd
Nov 20, 2024
Maintains: Overweight
Price Target: $9.5 → $3.55
Current: $2.51
Upside: +41.43%